Literature DB >> 29754642

Medical Therapy for Cushing's Syndrome in the Twenty-first Century.

Nicholas A Tritos1, Beverly M K Biller2.   

Abstract

Medical therapy has a useful adjunctive role in many patients with Cushing's syndrome. Patients with pituitary corticotroph adenomas who have received radiation therapy to the sella require medical therapy until the effects of radiation therapy occur. In addition, patients with Cushing's syndrome who cannot undergo surgery promptly, including those who are acutely ill and cannot safely undergo tumor resection, may benefit from medical therapy as a bridge to surgery. Other possible candidates for medical therapy are those with unresectable tumors or those whose tumor location remains unknown despite adequate diagnostic evaluation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cabergoline; Cushing’s disease; Cushing’s syndrome; Etomidate; Ketoconazole; Metyrapone; Mitotane; Pasireotide

Mesh:

Substances:

Year:  2018        PMID: 29754642     DOI: 10.1016/j.ecl.2018.01.006

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  9 in total

1.  Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2020-11-11       Impact factor: 3.889

Review 2.  Management challenges and therapeutic advances in congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Deborah P Merke
Journal:  Nat Rev Endocrinol       Date:  2022-04-11       Impact factor: 47.564

3.  Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.

Authors:  Maria Fleseriu; Stephan Petersenn; Beverly M K Biller; Pinar Kadioglu; Christophe De Block; Guy T'Sjoen; Marie-Christine Vantyghem; Libuse Tauchmanova; Judi Wojna; Michael Roughton; André Lacroix; John Newell-Price
Journal:  Clin Endocrinol (Oxf)       Date:  2019-10-01       Impact factor: 3.478

4.  Efficacy and safety of pasireotide for Cushing's disease: A protocol for systematic review and meta-analysis.

Authors:  Nairui Zhao; Xinxin Yang; Cuiliu Li; Jie Ma; Xiuping Yin
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

5.  Somatostatin receptors in normal and acromegalic somatotroph cells: the U-turn of the clinician to immunohistochemistry report - a review.

Authors:  Nina Ionovici; Mara Carsote; Dana Cristina Terzea; Anca Mihaela Predescu; Anne Marie Rauten; Mihaela Popescu
Journal:  Rom J Morphol Embryol       Date:  2020 Apr-Jun       Impact factor: 1.033

6.  Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study.

Authors:  Rosario Pivonello; Atanaska Elenkova; Maria Fleseriu; Richard A Feelders; Przemyslaw Witek; Yona Greenman; Eliza B Geer; Paola Perotti; Leonard Saiegh; Fredric Cohen; Giorgio Arnaldi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-07       Impact factor: 5.555

7.  Using Etomidate in a Two-month-old Infant with Cushing Syndrome due to Adrenocortical Carcinoma

Authors:  Ahreum Kwon; Yongha Choi; Jo Won Jung; Junghwan Suh; Ho-Seong Kim
Journal:  J Clin Res Pediatr Endocrinol       Date:  2020-11-30

8.  Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study.

Authors:  Maria Fleseriu; Chioma Iweha; Luiz Salgado; Tania Longo Mazzuco; Federico Campigotto; Ricardo Maamari; Padiporn Limumpornpetch
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-16       Impact factor: 5.555

9.  Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome.

Authors:  Eliza B Geer; Roberto Salvatori; Atanaska Elenkova; Maria Fleseriu; Rosario Pivonello; Przemyslaw Witek; Richard A Feelders; Marie Bex; Stina W Borresen; Soraya Puglisi; Beverly M K Biller; Fredric Cohen; Francesca Pecori Giraldi
Journal:  Pituitary       Date:  2020-11-20       Impact factor: 4.107

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.